NORTHLAND(BJ:430047)2024-02-25 16:00Financial Performance - The company reported a revenue of ¥59,675,141.95 for the reporting period, a decrease of 7.70% compared to ¥64,654,602.85 in the same period last year[4] - The net loss attributable to shareholders was ¥48,134,821.42, an improvement from a loss of ¥67,616,828.07 in the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥-56,534,346.89, compared to ¥-70,703,823.19 last year[4] - Basic earnings per share were reported at ¥-0.19, improving from ¥-0.26 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were ¥328,120,719.02, down 4.96% from ¥345,231,281.15 at the beginning of the period[4] - Shareholders' equity attributable to the company decreased by 22.79% to ¥153,212,884.84 from ¥198,440,667.75[5] - The company's net asset per share was ¥0.59, a decrease of 23.38% from ¥0.77 in the previous year[5] Operational Challenges - The decline in performance is primarily due to the ongoing R&D phase of the biopharmaceutical projects, which have not yet reached commercialization[7] - The company did not meet the third milestone for its equity incentive plan, leading to a reversal of previously accrued expenses, which positively impacted the net loss[7] Reporting and Auditing - Investors are cautioned that the reported figures are preliminary and unaudited, and the final data will be disclosed in the official annual report[8]